Clinical trial
A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of…
NCT00282386 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00282386 |
|---|---|
| Title | A Study to Evaluate the Effect of MK0966 (Rofecoxib) on the Recurrence of Colorectal Adenomas (0966-122) |
| Official title | A Multicenter, Randomized, Parallel-Group, Placebo-Controlled, Double-Blind Study With In-House Blinding to Determine the Effect of 156 Weeks of Treatment With MK0966 on the Recurrence of Neoplastic Polyps of the Large Bowel in Patients With a History of Colorectal Adenomas |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Adenoma |
| Intervention type | Drug |
| Interventions | MK0966, Rofecoxib / Duration of Treatment: 156 weeks, Placebo/ Duration of Treatment: 156 weeks |
| Enrollment | 2,586 |
| Start date | Dec 23, 1999 |
| Primary completion | Sep 1, 2004 |
| Completion | Sep 1, 2004 |
| First posted | Jan 26, 2006 |
| Last update posted | May 9, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: